Compare Skyworks Solutions Inc (SWKS) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Skyworks Solutions Inc vs Tango Therapeutics Inc. — how do they compare? Skyworks Solutions Inc trades at $76.8 (market cap $18.01B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Skyworks Solutions Inc is far larger — about 4.8× Tango Therapeutics Inc.'s market cap, and Skyworks Solutions Inc pays a 4.13% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Skyworks Solutions Inc for 50 Days and Tango Therapeutics Inc. for 0 Days on average.
| SWKS | TNGX | |
|---|---|---|
Market Cap | $18.01B | $3.75B |
Volume | 4,074,606 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $91.45 | $32.90 |
52-Week Low | $52.50 | $7.50 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | $17.89B | $2.77B |
Dividend Yield | 4.13% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Skyworks Solutions (SWKS) trades at $76.89, up 2.93% with a bearish technical signal despite recent earnings beats. The company shows declining revenue and profit margins over recent years, with 2025 revenue at $4.09B and net income of $477.10M. The pending Qorvo merger dominates news coverage, with analysts projecting significant synergies. Current valuation metrics include a P/E of 39.68 and P/S of 2.87, while cash flow trends show recent negative net cash flow of -$207.30M.
The investment outlook balances merger synergies against fundamental deterioration. Analyst consensus favors Buy (60%) with a $79.70 price target, but declining profitability and bearish technicals suggest caution. Key risks include integration challenges with Qorvo and ongoing margin pressure, while the RSI near 18 indicates potential oversold conditions for tactical opportunities.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
